The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
Clinics ordering large quantities from compounding pharmacies sometimes negotiate better per-unit prices
What Stage of Development Is Retatrutide Currently In
As for the limitation of this study, the relatively small sample size and relatively large variance of the metabolic measurements made the outcome non-significant
Studies have shown that patients often achieve around 5-10% body weight reduction by the 12-week mark, though individual results may vary
And women who are pregnant or breastfeeding need more